According to a report published
by Grand View Research, Inc.; the global Cancer Stem Cells Market is anticipated to reach a revenue
of around USD 1.6 billion by 2025. Increasing R&D initiatives for
developing effective treatments based on stem cells can propel market growth.
Rising awareness can further boost demand during the forecast period (2014 to
2025).
Significant rise in the number of
published studies and ongoing research projects on Cancer Stem Cells (CSCs) are
likely to create more growth opportunities for the market. These studies can
help healthcare professionals to improve insights into CSCs biology and their
signaling pathways. This factor is anticipated to bode well for the overall expansion
of the market during the forecast period.
Full Research Report
On Cancer Stem Cells Market Analysis: www.grandviewresearch.com/industry-analysis/cancer-stem-cells-market
Additionally, continuous progressions in experimental
approaches such as in-vitro assay system have helped scientist establish the
relationship between different tumors and their microenvironment. This has encouraged
development of a wide range of therapeutics portfolio for CSCs and key pathways
associated to restricting tumor development and providing satisfactory clinical
results. This factor is anticipated to play a crucial role in overall expansion
of the global market.
However, strict regulations
regarding approval and usage of stem cell therapies are likely to hinder the
market growth. Additionally, manufacturing and pharmacological issues related to
development of cancer cell therapy is projected to slow down market growth
during the forecast period.
Browse More Reports
Of This Category By Grand View Research At: www.grandviewresearch.com/industry/biotechnology
The worldwide cancer stem cells market is
segmented on the basis of mode of action, cancer forms, and region. As per mode
of action, the market is categorized into targeted cancerous stem cells and stem
cell-based cancer therapy. The targeted CSCs segment can be further segmented
into anti-CSC therapeutics and pathway inhibitors, surface marker-based,
immuno-evasion and targeting tumor microenvironment, nanoparticle-based
therapies, and others. Anti-CSC therapeutics is anticipated to hold a
significant market share over the forecast period due to rise in R&D
activities.
Stem cell-based cancer therapy
can be further bifurcated into autologous and allogeneic stem cell transplant. In
2016, the autologous stem cell transplant segment held the largest market share in
terms of revenue due to high adoption. Factors such as affordability and better
survival rate are other significant driving factors. The allogeneic segment is expected
to showcase notable CAGR during the forecast period due to increasing focus on
development of allogeneic cellular therapies.
Based on cancer forms, the market
can be split into breast, liver, blood, brain, lung, colorectal, bladder,
pancreatic, and other type of cancer. In 2016, breast segment accounted for the
largest market share due to high prevalence and availability of a large number
of therapeutics. Bladder cancer segment is expected to display the highest CAGR
of 10.47% over the forecast period due to high prevalence.
The lung cancer segment is likely
to register expansion at substantial CAGR over the projected period. This
growth can be attributed to increasing development activities due to prevalence
of lung malignance globally. In 2016, a team of researchers at the Department
of Cancer Biology, Mayo Clinic established a combination therapy using a
rheumatoid arthritis drug called auranofin to restrict the growth of lung CSCs.
Geographically, the market can be
divided into North America, Asia Pacific, Europe, Latin America, and Middle
East and Africa. In 2016, North America led the market in terms of revenue owing
to presence of large number of organizations involved in R&D activities. Presence
of a large number of well-established hospitals offering stem cell transplant
in the U.S. can bode well for regional market growth.
Asia Pacific is expected to be
the fastest growing region over the forecast period due to existence of
numerous cancer and stem cell research organizations. In addition, increasing government
funding and grants for research communities to accelerate cancer research can
further boost regional expansion.
Key companies operating in the cancer stem cells market
include OncoMed Pharmaceuticals, Inc.; Stemline Therapeutics, Inc.;
MacroGenics, Inc.; PromoCell GmbH; and Miltenyi Biotec. Companies are adopting
innovative strategies like facility expansion, new product launches, and
strategic alliances to take advantage of growing popularity of stem cell
therapy in clinical oncology.
Browse Press Release
of this Report:
https://www.grandviewresearch.com/press-release/global-cancer-stem-cells-market
https://www.grandviewresearch.com/press-release/global-cancer-stem-cells-market
About Grand View
Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/
No comments:
Post a Comment